Search Results - M. Mol

Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study by Sonia Roldan Munoz, Douwe Postmus, Sieta T. de Vries, Arna H. Arnardottir, İlknur Dolu, Hans Hillege, Hans Hillege, Peter G. M. Mol, Peter G. M. Mol

Connect to this object online.

Human keratinocyte sensitivity towards inflammatory cytokines varies with culture time by G. Elliott, D. van de Meent, J. van Dijk, M. Mol

Connect to this object online.

Measuring health-related stigma: Exploring challenges and research priorities to improve assessment by Marente M. Mol, Marlies J. Visser, Sarju S. Rai, Ruth M. H. Peters

Connect to this object online.

A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe by Jeroen V. Koomen, Jeroen V. Koomen, Jasper Stevens, Margje H. Monster-Simons, Margje H. Monster-Simons, Hiddo J. L. Heerspink, Peter G. M. Mol, Peter G. M. Mol

Connect to this object online.

Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting by Elisabeth Bakker, Peter G. M. Mol, Peter G. M. Mol, Peter G. M. Mol, João Nabais, João Nabais, Thorsten Vetter, Matthias Kretzler, John J. Nolan, Gert Mayer, Anna K. Sundgren, Hiddo J. L. Heerspink, Anja Schiel, Anja Schiel, Sieta T. de Vries, Maria F. Gomez, Friedrich Schulze, Dick de Zeeuw, Michelle J. Pena, for the BEAt-DKD Consortium

Connect to this object online.

Precision medicine in regulatory decision making: Biomarkers used for patient selection in European Public Assessment Reports from 2018 to 2020 by Elisabeth Bakker, Viktoriia Starokozhko, Jet W. M. Kraaijvanger, Hiddo J. L. Heerspink, Peter G. M. Mol

Connect to this object online.

Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment by Rianne A. Weersink, Rianne A. Weersink, Lotte Timmermans, Lotte Timmermans, Margje H. Monster-Simons, Margje H. Monster-Simons, Peter G. M. Mol, Peter G. M. Mol, Herold J. Metselaar, Sander D. Borgsteede, Sander D. Borgsteede, Katja Taxis

Connect to this object online.

The effect of a pharmaceutical transitional care program on rehospitalisations in internal medicine patients: an interrupted-time-series study by Fatma Karapinar-Çarkıt, Sander D. Borgsteede, Marjo J. A. Janssen, Marlies Mak, Nimet Yildirim, Carl E. H. Siegert, Peter G. M. Mol, Toine C. G. Egberts, Patricia M. L. A. van den Bemt

Connect to this object online.

The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy's multi-stakeholder pre-convention questionnaire by Lauren Van Haesendonck, Jörg Ruof, Thomas Desmet, Walter Van Dyck, Steven Simoens, Isabelle Huys, Rosa Giuliani, Mondher Toumi, Christian Dierks, Juliana Dierks, Antonella Cardone, Francois Houÿez, Mira Pavlovic, Michael Berntgen, Peter G.M. Mol, Anja Schiel, Wim Goettsch, Fabrizio Gianfrate, Stefano Capri, James Ryan, Pierre Ducournau, Oriol Solà-Morales, Elaine Julian

Connect to this object online.

A physiological glucocorticoid rhythm is an important regulator of brown adipose tissue function by Jan Kroon, Maaike Schilperoort, Wietse In het Panhuis, Rosa van den Berg, Lotte van Doeselaar, Cristy R.C. Verzijl, Nikki van Trigt, Isabel M. Mol, Hetty H.C.M. Sips, Jose K. van den Heuvel, Lisa L. Koorneef, Ronald J. van der Sluis, Anna Fenzl, Florian W. Kiefer, Sabine Vettorazzi, Jan P. Tuckermann, Nienke R. Biermasz, Onno C. Meijer, Patrick C.N. Rensen, Sander Kooijman

Connect to this object online.